News

Sai Parenterals Ltd share price declined by 1.35% to Rs 579.4 after the company`s net profit plunged by 39.82% to Rs 7.92 crore, while revenue from operations slipped slightly by 9.73% to Rs 178.67 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, gaining 4.41%. It has improved by 1.16% over last one week and advanced by 11.70% in last one month while the market capitalization of Sai Parenterals Ltd has gained 11.76% and 20.76% in the same period respectively. Profit before tax (PBT) of Sai Parenterals Ltd stood at Rs 9.79 crore in Q2 FY26, jumping 387.06% year-on-year, and crashing by 20.98% quarter-on-quarter. EBITDA came in at Rs 20 crore, surging by 452.51% YoY and dropping 14.78% sequentially. Total expenses softened by 9.31% to Rs 163.26 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 116.12 crore, growing marginally by 1.73% YoY, while employee benefits expense was at Rs 11.54 crore, registering a marginal contraction of 5.56% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 6.08% to Rs 163.11 crore, while net profit saw a strong growth of 71.38% to Rs 14.43 crore, compared to previous TTM. EBITDA jumped by 2802% to Rs 38.74 crore, and PBT soared 58.52% to Rs 19.91 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 33.15 crore in FY26, as against Rs 29.76 crore in FY25.

Sai Parenterals will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Sai Parenteral`s will hold a meeting of the Board of Directors of the Company on 11 August 2026.

Sai Parenterals announced that the company`s subsidiary Noumed Pharmaceuticals had entered OTC medicines supply agreement with Australia`s leading pharmacy network with contract valued at Australian Dollars (AUD) 202 millions (equivalent to Rs 1300 crore; 1 AUD = INR 64.5). The agreement is valid for a period of 7.5 years with a further option of 3 years extension upon mutual consent.

Sai Parenterals has received a purchase order valued at USD 11 million at an exchange rate of Rs 95 (Rs 104.50 crore) from PILL CORP, Bulacan, Philippines. The contract is for supply of anti TB products for the Philippines market on exclusivity basis for a period of 10 years.